OncoMatch/Clinical Trials/NCT05772208
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
Is NCT05772208 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Camrelizumab and Nimotuzumab for nasopharyngeal carcinoma.
Treatment: Camrelizumab · Nimotuzumab · neoadjuvant chemotherapy and CCRT — The goal of this multicenter randomized non-inferior study is to compare the additon of camrelizumab or nimotuzumab to neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma patients whose EBV DNA remained detectable after one cycle neoadjuvant chemotherapy using GP regimen. The main question it aims to answer is: whether the addition of carrilizumab or nituzumab improve the treatment outcomes in the relatively poor prognostic patients identified by the response of EBV DNA. Participants will be randomized to the combination of carrilizumab and standard treatment , the combination of nituzumab and standard treatment or the standard treatment alone if their EBV DNA didn't decrease to undetectable level post first cycle of neoadjuvant chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: EGFR overexpression
EGFR+
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy
Cannot have received: chemotherapy
Cannot have received: targeted therapy
Lab requirements
Blood counts
HGB ≥90 g/L, WBC ≥4×10^9 /L, PLT ≥100×10^9 /L
Kidney function
serum creatinine < 1x ULN
Liver function
ALT, AST < 1.5x ULN; total bilirubin < 1.0x ULN
Hemoglobin (HGB) ≥90 g/L, white blood cell (WBC) ≥4×10^9 /L, platelet (PLT) ≥100×10^9 /L. Liver function: ALT, AST < 1.5x ULN, total bilirubin <1.0x ULN. Renal function: serum creatinine <1x ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05772208 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR overexpression is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IVA is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify